Comparing Apls And Oranges: Caution With The Use Of Direct-Acting Oral Anticoagulants (Doacs) Instead Of Warfarin In The Treatment Of Antiphospholipid Syndrome (Apls)

A 63-year-old woman with known antiphospholipid syndrome (APLS) presented with catastrophic APLS and multiorgan dysfunction after a change in her anticoagulation from warfarin to rivaroxaban. Evidence suggests direct-acting oral anticoagulants (DOACs) like rivaroxaban may be less effective than warfarin in secondary prevention of thrombotic events in high-risk APLS patients.